دورية أكاديمية

Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.

التفاصيل البيبلوغرافية
العنوان: Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.
المؤلفون: Edson KZ; Department of Medicinal Chemistry and ‡Department of Pharmaceutics, School of Pharmacy at the University of Washington , Box 357610, Seattle, Washington 98105, United States., Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, Rettie AE
المصدر: Biochemistry [Biochemistry] 2013 Nov 19; Vol. 52 (46), pp. 8276-85. Date of Electronic Publication: 2013 Nov 07.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370623 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4995 (Electronic) Linking ISSN: 00062960 NLM ISO Abbreviation: Biochemistry Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, American Chemical Society.
مواضيع طبية MeSH: Cytochrome P-450 Enzyme System/*metabolism , Vitamin K 2/*analogs & derivatives, Cytochrome P-450 CYP4A/metabolism ; Cytochrome P450 Family 4 ; Humans ; Hydroxylation ; Kinetics ; Microsomes, Liver/enzymology ; Vitamin K 2/metabolism
مستخلص: Vitamin K plays an essential role in many biological processes including blood clotting, maintenance of bone health, and inhibition of arterial calcification. A menaquinone form of vitamin K, MK4, is increasingly recognized for its key roles in mitochondrial electron transport, as a ligand for the nuclear receptor SXR, which controls the expression of genes involved in transport and metabolism of endo- and xenobiotics, and as a pharmacotherapeutic in the treatment of osteoporosis. Although cytochrome P450 (CYP) 4F2 activity is recognized as an important determinant of phylloquinone (K1) metabolism, the enzymes involved in menaquinone catabolism have not been studied previously. CYP4F2 and CYP4F11 were expressed and purified and found to be equally efficient as in vitro catalysts of MK4 ω-hydroxylation. CYP4F2, but not CYP4F11, catalyzed sequential metabolism of MK4 to the ω-acid without apparent release of the intermediate aldehyde. The ω-alcohol could also be metabolized to the acid by microsomal NAD(+)-dependent alcohol and aldehyde dehydrogenases. LC-MS/MS analysis of trypsinized human liver microsomes (using a surrogate peptide approach) revealed the mean concentrations of CYP4F2 and CYP4F11 to be 14.3 and 8.4 pmol/mg protein, respectively. Microsomal MK4 ω-hydroxylation activities correlated with the CYP4F2 V433M genotype but not the CYP4F11 D446N genotype. Collectively, these data expand the lexicon of vitamin K ω-hydroxylases to include the 'orphan' P450 CYP4F11 and identify a common variant, CYP4F2 (rs2108622), as a major pharmacogenetic variable influencing MK4 catabolism.
References: Mol Pharmacol. 2012 Oct;82(4):679-86. (PMID: 22772592)
J Pharm Sci. 2013 Mar;102(3):787-93. (PMID: 23280364)
J Biol Chem. 2008 Apr 25;283(17):11270-9. (PMID: 18083713)
Front Biosci (Landmark Ed). 2012 Jun 01;17:2476-94. (PMID: 22652793)
Food Nutr Res. 2012;56:. (PMID: 22489224)
J Med Chem. 2012 Feb 23;55(4):1553-8. (PMID: 22250752)
J Med Chem. 2011 Jun 23;54(12):4269-73. (PMID: 21561094)
Nature. 2010 Nov 4;468(7320):117-21. (PMID: 20953171)
Biochemistry. 2011 Nov 22;50(46):10041-51. (PMID: 22004098)
FASEB J. 2008 Jun;22(6):2064-71. (PMID: 18182499)
J Biol Chem. 1989 May 5;264(13):7584-9. (PMID: 2708380)
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304. (PMID: 15364545)
Anal Chem. 2005 Feb 1;77(3):757-63. (PMID: 15679341)
Science. 2012 Jun 8;336(6086):1306-10. (PMID: 22582012)
Physiol Genomics. 2007 Jun 19;30(1):74-81. (PMID: 17341693)
Free Radic Res. 2006 May;40(5):445-53. (PMID: 16551570)
Drug Metab Dispos. 2012 May;40(5):852-5. (PMID: 22318656)
Int J Cancer. 2011 May 1;128(9):1999-2009. (PMID: 21387284)
Blood. 2007 Jun 15;109(12):5270-5. (PMID: 17327402)
J Agric Food Chem. 2006 Jan 25;54(2):463-7. (PMID: 16417305)
Biochem Biophys Res Commun. 2001 Feb 2;280(4):1135-41. (PMID: 11162645)
Arch Biochem Biophys. 2010 Feb 1;494(1):86-93. (PMID: 19932081)
Br J Nutr. 2006 Feb;95(2):260-6. (PMID: 16469140)
Nature. 1996 Mar 7;380(6569):41-6. (PMID: 8598903)
Annu Rev Nutr. 2009;29:89-110. (PMID: 19400704)
Blood. 2007 Mar 15;109(6):2419-23. (PMID: 17110451)
Yakugaku Zasshi. 2003 May;123(5):369-75. (PMID: 12772594)
Genomics. 2000 Sep 1;68(2):161-6. (PMID: 10964514)
Biofactors. 1999;9(2-4):111-9. (PMID: 10416022)
Analyst. 2004 Jan;129(1):45-50. (PMID: 14737582)
Blood. 2008 Aug 15;112(4):1022-7. (PMID: 18535201)
J Biol Chem. 1999 Aug 20;274(34):23833-40. (PMID: 10446146)
Protein Expr Purif. 2000 Jun;19(1):173-8. (PMID: 10833404)
J Nutr. 1998 May;128(5):785-8. (PMID: 9566982)
Mol Pharmacol. 2009 Jun;75(6):1337-46. (PMID: 19297519)
Biochim Biophys Acta. 2006 Oct;1760(10):1482-8. (PMID: 16844298)
J Nutr Biochem. 2013 Apr;24(4):624-8. (PMID: 22819559)
Arch Biochem Biophys. 2008 Oct 1;478(1):59-68. (PMID: 18662666)
J Biol Chem. 2002 Jul 12;277(28):25290-6. (PMID: 11997390)
Blood. 2007 Apr 15;109(8):3279-83. (PMID: 17158229)
معلومات مُعتمدة: U01 GM092676 United States GM NIGMS NIH HHS; R37 CA090426 United States CA NCI NIH HHS; R01 GM109743 United States GM NIGMS NIH HHS; R01 GM068797 United States GM NIGMS NIH HHS; U01 GM92676 United States GM NIGMS NIH HHS
المشرفين على المادة: 11032-49-8 (Vitamin K 2)
27Y876D139 (menatetrenone)
9035-51-2 (Cytochrome P-450 Enzyme System)
EC 1.14.14.1 (Cytochrome P450 Family 4)
EC 1.14.14.78 (CYP4F11 protein, human)
EC 1.14.14.78 (CYP4F2 protein, human)
EC 1.14.15.3 (Cytochrome P-450 CYP4A)
تواريخ الأحداث: Date Created: 20131022 Date Completed: 20140121 Latest Revision: 20211021
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC3900248
DOI: 10.1021/bi401208m
PMID: 24138531
قاعدة البيانات: MEDLINE
الوصف
تدمد:1520-4995
DOI:10.1021/bi401208m